Welcome to our dedicated page for Gyre Therapeutics SEC filings (Ticker: GYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gyre Therapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with U.S. and China operations, revenue from Gyre Pharmaceuticals, and a pipeline centered on anti-fibrotic therapies and targeted protein degradation assets. Form 8-K reports cover operating results, business updates, CDE/NMPA regulatory disclosures for F351, and clinical-program updates for Hydronidone and pirfenidone.
Proxy and material-event filings describe governance matters, shareholder voting items, material agreements, capital-structure disclosures and the completed Cullgen acquisition, including preferred-stock and common-stock conversion mechanics. The record also includes Regulation FD disclosures addressing commercial products, research spending and pipeline development.
Gyre Therapeutics, Inc. is registering 30,221,531 shares of Common Stock for resale by selling stockholders. The registration covers up to 11,735,356 Common Shares and 18,486,175 Conversion Series B Shares issuable upon conversion of 3,697,235 Series B Preferred Shares, with conversion subject to stockholder approval required by Nasdaq (the "Conversion Approval").
The company states it will receive no proceeds from sales of the Resale Shares; net proceeds will be received by the selling stockholders. The filing arises from the May 4, 2026 merger with Cullgen and implements registration rights under a Registration Rights Agreement. Shares outstanding were 111,488,849 as of May 31, 2026.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a series of option exercises paired with open-market sales of common stock. On June 9, 10, and 18, he exercised stock options at $0.75 per share to acquire a total of 11,000 shares of common stock, then sold 11,000 shares in open-market transactions at prices reported around $6.15–$6.35 per share. A footnote states some sales were reported as a weighted average with individual trades between $6.20 and $6.30 per share. After these transactions, Ye directly holds 700,000 shares of Gyre Therapeutics common stock.
Gyre Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. There were 96,994,001 shares of common stock entitled to vote as of the April 16, 2026 record date.
Stockholders elected Class II directors David M. Epstein, Ph.D. and Dan Weng, M.D. to serve until the 2029 annual meeting. A non-binding advisory vote approved executive compensation. Stockholders also ratified Grant Thornton Zhitong Certified Public Accountants LLP as independent auditor for 2026 and approved issuing common stock upon conversion of Series B Convertible Preferred Stock in accordance with Nasdaq Listing Rule 5635(a).
GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported a same‑day option exercise and share sale. He exercised options to acquire 2,800 shares of common stock at an exercise price of $0.75 per share, then sold 2,800 shares in an open‑market transaction at a weighted average price of $6.17 per share.
After these transactions, Ye directly holds 700,000 shares of common stock. The exercised options covered 2,800 shares of common stock originally granted as a stock option (right to buy) that was fully vested.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported an exercise-and-sell sequence in company stock. On June 9 and 10, 2026, he sold a total of 20,918 shares of common stock in open-market transactions at reported prices of $6.14 and $6.21 per share, with actual sales executed across price ranges detailed in the footnotes.
On the same dates, he exercised stock options to acquire the same total of 20,918 shares of common stock at an exercise price of $0.75 per share. Following these transactions, he directly held 700,000 shares of common stock. The options exercised were reported as vested in full, and no remaining derivative positions are listed in this filing.
GYRE THERAPEUTICS, INC. reported a Form 4 showing that GC and Corporate Secretary Joshua Benjamin Bergmann received a grant of stock options to acquire 50,000 shares of common stock at an exercise price of $6.05 per share. These options expire on June 8, 2036. According to the vesting terms, 25% of the grant will vest on June 8, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to continued service. After this grant, Bergmann holds 50,000 derivative securities directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
GYRE THERAPEUTICS, INC. reported that Chief Executive Officer Luo Ying received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $6.05 per share and expire on June 8, 2036.
According to the grant terms, 25% of the options will vest on June 8, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Luo Ying’s continued service. Following this award, the filing shows 120,000 derivative securities held directly.
GYRE Therapeutics Chief Operating Officer Ye Weiguo reported an exercise-and-sell sequence in company stock. On June 4, 2026 and June 5, 2026, he exercised stock options to acquire a total of 34,976 shares of common stock at an exercise price of $0.75 per share and then sold the same number of shares in open-market transactions.
The 19,575-share sale on June 4 occurred at a weighted average price of $6.13 per share in trades ranging from $6.05 to $6.30, while the 15,401-share sale on June 5 was at a weighted average price of $6.40 per share in trades ranging from $6.15 to $6.60. After these transactions, Weiguo directly holds 700,000 shares of GYRE common stock.
Gyre Therapeutics, Inc. furnished an updated corporate presentation highlighting its fully integrated biopharmaceutical platform focused on fibrosis, inflammatory diseases, cancer and pain, following the recent acquisition of Cullgen.
The company’s first product, ETUARY™ (pirfenidone), is described as a market leader in organ fibrosis in China, with new line-extension programs in radiation-induced lung injury and pneumoconiosis supported by encouraging preclinical and phase 2 data.
Lead liver-fibrosis candidate F351 (hydronidone) showed ≥1-stage fibrosis regression at Week 52 in 52.85% of patients versus 29.84% on placebo (p=0.0002) in a China phase 3 trial of CHB‑associated liver fibrosis; an NDA was accepted by the China NMPA in May 2026, and a U.S. IND for MASH has been filed. The deck also outlines a broad targeted protein degrader and degrader‑antibody conjugate pipeline, including CDK2/Cyclin E and TYK2/JAK1 degraders and TRK and GSPT1 programs, supported by China-based discovery, development and manufacturing operations and a global workforce of about 740 employees.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported option exercises paired with open-market sales of common stock. On May 22 and May 26, he exercised stock options to acquire a total of 7,500 shares of common stock at an exercise price of $0.75 per share and sold 7,500 shares in open-market transactions.
The reported sale prices include $6.0800 per share for 3,500 shares and a weighted average price of $6.1001 per share for 4,000 shares, with individual trades ranging from $6.04 to $6.1051. Following these transactions, Ye’s directly held common stock position is reported at approximately 700,000 shares, indicating the activity mainly reflects option-related liquidity rather than a large change in overall ownership.